Study on Lenti-HPV-07 Immunotherapy for HPV-Related Cervical or Oropharyngeal Cancer
Sponsor: Theravectys S.A.
ClinicalTrials ID:NCT06319963
This clinical trial is testing a new treatment called Lenti-HPV-07 to see if it is safe and effective for patients with cervical or oropharyngeal cancer caused by the Human Papilloma Virus (HPV).
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this study is to evaluate the safety and effectiveness of a new treatment called Lenti-HPV-07 for patients with cancer caused by the Human Papilloma Virus (HPV). The study aims to find out if Lenti-HPV-07 is safe to use and if it can trigger an immune response to fight the cancer. Participants will be placed into one of two groups based on their type of cancer: one group for those with recurrent or metastatic cancer, and another for those newly diagnosed with locally advanced cancer. After completing the treatment, participants will be monitored for up to one year through clinic visits or phone calls, with follow-ups occurring four weeks after the last treatment and then every three months.
Eligibility Criteria
Inclusion Criteria
- Have a confirmed diagnosis of invasive HPV-related oropharyngeal or cervical cancer.
- Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
- Have adequate liver, kidney, lung, and blood cell function.
Exclusion Criteria
- Have a positive test for HIV, active hepatitis C, or hepatitis B infection.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Florida Cancer Specialists (from Sarah Canon research Institute) | 32827 | Orlando | Florida |
| Tampa General Hospital | 33606 | Tampa | Florida |
| Moffitt Cancer Center | 33612 | Tampa | Florida |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.